Pseudomyxoma peritonei laboratory findings: Difference between revisions
Jump to navigation
Jump to search
Nima Nasiri (talk | contribs) |
|||
| (2 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Pseudomyxoma peritonei}} | {{Pseudomyxoma peritonei}} | ||
{{CMG}}{{AE}}{{Nnasiri | {{CMG}}{{AE}}{{Nnasiri}} | ||
==Overview== | ==Overview== | ||
The [[laboratory]] findings associated with pseudomyxoma peritonei are increased levels of tumor markers such as [[carcinoembryonic antigen]] (CEA), [[CA-19-9|carbohydrate antigen 19-9]] ([[CA19-9]]), [[CA-125|carbohydrate antigen 125]] ([[CA125]]). | The [[laboratory]] findings associated with pseudomyxoma peritonei are increased levels of [[Tumor marker|tumor markers]] such as [[carcinoembryonic antigen]] ([[CEA]]), [[CA-19-9|carbohydrate antigen 19-9]] ([[CA19-9]]), [[CA-125|carbohydrate antigen 125]] ([[CA125]]). | ||
==Laboratory Findings== | ==Laboratory Findings== | ||
The laboratory findings associated with pseudomyxoma peritonei are increased levels of tumor markers such as:<ref name="pmid17510772">{{cite journal |vauthors=Baratti D, Kusamura S, Martinetti A, Seregni E, Laterza B, Oliva DG, Deraco M |title=Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy |journal=Ann. Surg. Oncol. |volume=14 |issue=8 |pages=2300–8 |date=August 2007 |pmid=17510772 |doi=10.1245/s10434-007-9393-9 |url=}}</ref><ref name="pmid15932563">{{cite journal |vauthors=Alexander-Sefre F, Chandrakumaran K, Banerjee S, Sexton R, Thomas JM, Moran B |title=Elevated tumour markers prior to complete tumour removal in patients with pseudomyxoma peritonei predict early recurrence |journal=Colorectal Dis |volume=7 |issue=4 |pages=382–6 |date=July 2005 |pmid=15932563 |doi=10.1111/j.1463-1318.2005.00773.x |url=}}</ref> | The laboratory findings associated with pseudomyxoma peritonei are increased levels of [[Tumor marker|tumor markers]] such as:<ref name="pmid17510772">{{cite journal |vauthors=Baratti D, Kusamura S, Martinetti A, Seregni E, Laterza B, Oliva DG, Deraco M |title=Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy |journal=Ann. Surg. Oncol. |volume=14 |issue=8 |pages=2300–8 |date=August 2007 |pmid=17510772 |doi=10.1245/s10434-007-9393-9 |url=}}</ref><ref name="pmid15932563">{{cite journal |vauthors=Alexander-Sefre F, Chandrakumaran K, Banerjee S, Sexton R, Thomas JM, Moran B |title=Elevated tumour markers prior to complete tumour removal in patients with pseudomyxoma peritonei predict early recurrence |journal=Colorectal Dis |volume=7 |issue=4 |pages=382–6 |date=July 2005 |pmid=15932563 |doi=10.1111/j.1463-1318.2005.00773.x |url=}}</ref> | ||
*[[Carcinoembryonic antigen]] ([[CEA]]) | *[[Carcinoembryonic antigen]] ([[CEA]]) | ||
*[[CA-19-9|Carbohydrate antigen 19-9]] ([[CA19-9]]) | *[[CA-19-9|Carbohydrate antigen 19-9]] ([[CA19-9]]) | ||
*[[CA-125|Carbohydrate antigen 125]] ([[CA125]]) | *[[CA-125|Carbohydrate antigen 125]] ([[CA125]]) | ||
These tumor markers are useful for postoperative follow-up and prediciton of the completeness of cytoreductive surgery.<ref name="pmid17510772">{{cite journal |vauthors=Baratti D, Kusamura S, Martinetti A, Seregni E, Laterza B, Oliva DG, Deraco M |title=Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy |journal=Ann. Surg. Oncol. |volume=14 |issue=8 |pages=2300–8 |date=August 2007 |pmid=17510772 |doi=10.1245/s10434-007-9393-9 |url=}}</ref> | These [[Tumor marker|tumor markers]] are useful for postoperative follow-up and prediciton of the completeness of cytoreductive surgery.<ref name="pmid17510772">{{cite journal |vauthors=Baratti D, Kusamura S, Martinetti A, Seregni E, Laterza B, Oliva DG, Deraco M |title=Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy |journal=Ann. Surg. Oncol. |volume=14 |issue=8 |pages=2300–8 |date=August 2007 |pmid=17510772 |doi=10.1245/s10434-007-9393-9 |url=}}</ref> | ||
== References == | == References == | ||
{{Reflist| | {{Reflist|2}} | ||
[[Category:Gasteroenterology]] | [[Category:Gasteroenterology]] | ||
Latest revision as of 13:28, 2 April 2019
|
Pseudomyxoma peritonei Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Pseudomyxoma peritonei laboratory findings On the Web |
|
American Roentgen Ray Society Images of Pseudomyxoma peritonei laboratory findings |
|
Risk calculators and risk factors for Pseudomyxoma peritonei laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Nima Nasiri, M.D.[2]
Overview
The laboratory findings associated with pseudomyxoma peritonei are increased levels of tumor markers such as carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), carbohydrate antigen 125 (CA125).
Laboratory Findings
The laboratory findings associated with pseudomyxoma peritonei are increased levels of tumor markers such as:[1][2]
These tumor markers are useful for postoperative follow-up and prediciton of the completeness of cytoreductive surgery.[1]
References
- ↑ 1.0 1.1 Baratti D, Kusamura S, Martinetti A, Seregni E, Laterza B, Oliva DG, Deraco M (August 2007). "Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy". Ann. Surg. Oncol. 14 (8): 2300–8. doi:10.1245/s10434-007-9393-9. PMID 17510772.
- ↑ Alexander-Sefre F, Chandrakumaran K, Banerjee S, Sexton R, Thomas JM, Moran B (July 2005). "Elevated tumour markers prior to complete tumour removal in patients with pseudomyxoma peritonei predict early recurrence". Colorectal Dis. 7 (4): 382–6. doi:10.1111/j.1463-1318.2005.00773.x. PMID 15932563.